Company: PETVW
Filing Date: 2025-11-14
Form Type: 10-Q
Source: 0001493152-25-023398
Chunk: 20

Company: PetVivo Holdings, Inc.
Filing Date: 2025-11-14
Form: 10-Q
Item: Part I, Item 1
Chunk 20
---
 3,896,199  
     3,896,199 
  
    Accumulated Amortization 
     (3,874,575) 
     (3,872,474)
  
    Total net 
    $21,624  
    $23,725 

Amortization
expense was $870
and $1,382
for the three months ended September 30, 2025 and 2024, respectively. Amortization expense was $2,100
and $3,616
for the six months ended September 30, 2025 and 2024, respectively. The Company currently has twelve (12) U.S. and foreign patents issued, with three (3) additional patent applications
pending with the USPTO.

NOTE
6 –LICENSING AGREEMENTS

The
components of licensing agreements, all of which are finite-lived, were as follows:

SCHEDULE OF LICENSING AGREEMENTS 

    September 30, 2025  
    March 31, 2025 
  
    License Agreements 
    $2,800,000  
    $2,000,000 
  
    Accumulated Amortization 
     (255,111) 
     (50,000)
  
    Total net 
    $2,544,889  
    $1,950,000 

In
February 2025, the Company signed an exclusive licensing agreement with VetStem, Inc. to market and sell their PrecisePRP™ (Platelet-Rich
Plasma) for both canine and equine products. The exclusive licensing agreement is a five5-year
agreement whereby the Company paid an initial licensing fee of $2,000,000,
which was paid in a combination of $500,000
cash, $1,000,000
in stock issuances and $500,000
in future contract payments. The Company paid $125,000
in contract payments in August 2025. Future contract payments
included in accrued expenses as of September 30, 2025, and March 31, 2025 were $375,000
and $500,000,
respectively. The licensing fee is amortized over sixty (60)
months, the term of the agreement. The licensing agreement also has a nominal royalty fee payment between 3%
to 4.5%,
commencing in the seventh month of the licensing agreement